COMPETE Phase III Clinical Trial
will evaluate the efficacy and safety of Targeted Radionuclide Therapy with 177Lu-Edotreotide / Solucin® in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET).
Patient Information
Patients and interested parties will find further information on the COMPETE trial subjects’ inclusion criteria as well as our listed participating clinical centers.
Healthcare Professionals
The trial will be conducted worldwide in 11 countries at 33 sites and is now open for recruitment. Healthcare professionals who are interested in enrolling patients will find comprehensive background information on this site.